An antibody–drug conjugate targeting tissue factor (TF/CD142) with a human IgG1 linked to the cytotoxic payload monomethyl auristatin E (MMAE). Upon binding TF, it is internalized and releases MMAE to inhibit microtubules, causing G2/M arrest and apoptosis; may also engage Fc-mediated effector functions.
Anti–tissue factor (TF/CD142) IgG1 linked via a protease-cleavable linker to monomethyl auristatin E (MMAE). After TF binding and internalization, MMAE is released to inhibit tubulin polymerization, inducing G2/M arrest and apoptosis; may also engage Fc-mediated effector functions and modestly interfere with TF/FVIIa signaling.
YES
DIRECT
The anti–TF ADC binds TF (CD142) on the cell surface, is internalized, and releases MMAE via linker cleavage; MMAE disrupts microtubules, causing G2/M arrest and apoptosis (with possible added Fc-mediated cytotoxicity).
An antibody–drug conjugate targeting tissue factor (TF/CD142) with a human IgG1 linked to the cytotoxic payload monomethyl auristatin E (MMAE). Upon binding TF, it is internalized and releases MMAE to inhibit microtubules, causing G2/M arrest and apoptosis; may also engage Fc-mediated effector functions.
Anti–tissue factor (TF/CD142) IgG1 linked via a protease-cleavable linker to monomethyl auristatin E (MMAE). After TF binding and internalization, MMAE is released to inhibit tubulin polymerization, inducing G2/M arrest and apoptosis; may also engage Fc-mediated effector functions and modestly interfere with TF/FVIIa signaling.
NO
INDIRECT
The ADC targets tissue factor (TF) on the cell surface; after TF-mediated internalization, MMAE binds tubulin beta and disrupts microtubules to cause G2/M arrest and apoptosis. Tubulin is not the targeted antigen, so cells expressing only tubulin are not selectively killed.
An antibody–drug conjugate targeting tissue factor (TF/CD142) with a human IgG1 linked to the cytotoxic payload monomethyl auristatin E (MMAE). Upon binding TF, it is internalized and releases MMAE to inhibit microtubules, causing G2/M arrest and apoptosis; may also engage Fc-mediated effector functions.
Anti–tissue factor (TF/CD142) IgG1 linked via a protease-cleavable linker to monomethyl auristatin E (MMAE). After TF binding and internalization, MMAE is released to inhibit tubulin polymerization, inducing G2/M arrest and apoptosis; may also engage Fc-mediated effector functions and modestly interfere with TF/FVIIa signaling.
NO
INDIRECT
The ADC targets tissue factor (TF/CD142) on cells, is internalized, and releases MMAE to inhibit microtubules and induce apoptosis. Binding to FVIIa only interferes with TF/FVIIa coagulation signaling and does not deliver cytotoxic payload to FVIIa-expressing cells.
Anti-CD38 IgG1 monoclonal antibody that mediates ADCC, CDC, and ADCP and induces apoptosis of CD38+ clonal plasma cells.
Human IgG1κ monoclonal antibody targeting CD38 on clonal plasma cells; binding triggers immune effector–mediated killing (ADCC, CDC, ADCP) and direct apoptosis, and depletes CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs), resulting in antitumor activity.
YES
DIRECT
Anti-CD38 IgG1 binds CD38 on target cells and triggers immune effector killing (ADCC by NK cells, CDC via complement, ADCP by phagocytes) and can induce direct apoptosis upon binding/crosslinking.
EGFR-targeting IgG1 monoclonal antibody that blocks ligand binding and receptor activation, inhibiting MAPK/ERK and PI3K/AKT signaling; may also trigger ADCC.
Chimeric IgG1 monoclonal antibody that binds the extracellular domain of EGFR, blocking ligand binding and receptor dimerization/activation, thereby inhibiting downstream MAPK/ERK and PI3K/AKT signaling to suppress tumor cell proliferation; its Fc domain can also trigger antibody-dependent cellular cytotoxicity (ADCC).
YES
DIRECT
Cetuximab binds EGFR on target cells and its IgG1 Fc engages Fcγ receptors on NK cells/macrophages to trigger ADCC (and some CDC), leading to killing of EGFR-expressing cells; EGFR signaling blockade is mainly antiproliferative.